DSP-3025 A Phase 1 Study of Healthy Male Volunteers

NCT01124396 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2022-04-12

No results posted yet for this study

Summary

Investigate safety/tolerability after repeated weekly doses intranasal administration of DSP-3025 comparator placebo to healthy male volunteers

Conditions

  • Healthy

Interventions

DRUG

DSP-3025

DRUG

Placebo

Sponsors & Collaborators

  • Sumitomo Pharma Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
20 Years
Max Age
39 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-08-31
Completion
2012-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01124396 on ClinicalTrials.gov